Leading international law firm Herbert Smith Freehills has advised China International Capital Corporation Hong Kong Securities Limited as the sole sponsor of Sunho Biologics, Inc. (02898.HK)’s listing on the Main Board of the Hong Kong Stock Exchange.
Sunho Biologics is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialisation of biologics that regulate immune microenvironment by directly modulating both the innate and adaptive immune systems. The company has developed various types of immunotherapies including immunocytokines to treat cancers and autoimmune diseases, with its products among the most clinically advanced immunocytokine candidates.
We congratulate Sunho Biologics on its listing on the Hong Kong Stock Exchange,” said Hong Kong partner Jason Sung. “We are delighted to have worked with the sole sponsor and the company on this IPO and wish them continued success.”
Herbert Smith Freehills leads the legal market in advising sponsors and underwriters on Hong Kong IPOs. In the past two years, the firm has advised on 15 successful listings in Hong Kong, ranking fifth among 70 international and local law firms in Hong Kong, according to RyanBen Capital. The firm has advised on over 20 healthcare and biotech listings since the Hong Kong Stock Exchange introduced its new regime for biotech listings in 2018.
Partners Jason Sung and Jin Kong* jointly led a cross-office team advising the sole sponsor, assisted by senior associate Jaime Fong, counsel Sean Ji, associates Cyrus Wong and Bryan Zhu, registered foreign lawyer (New York, USA) Haiyun Chen, legal manager Hilary Chong, trainees Charles Chan, Betty Zhou and Jimmy Chu.
Legal manager Marine Jin led Herbert Smith Freehills Kewei Joint Operation’s Digital Legal Delivery business to provide high-efficiency solutions for verification and other document-intensive processes during the listing, assisted by legal analyst Jean Zhou, and legal analysts Chunqin Li, Ling Sun and Mia Jin.
